Status | Study |
Terminated |
Study Name: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) Condition: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1 Date: 2011-05-27 Interventions: Drug: Everolimus (RAD001) oral daily dosing of tablet starting with 2.5 mg |
Completed |
Study Name: Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Condition: Neurofibromatosis NF1 Date: 2011-01-11 Interventions: Drug: Tasigna Following enrollment each subject will initially receive Tasigna orally at 200 mg twice da |
Active, not recruiting |
Study Name: Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Condition: Neurofibromatosis Neurofibromas Date: 2010-06-08 Interventions: Drug: Gleevec Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with |
Terminated |
Study Name: First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas Condition: Cutaneous Neurofibromas Date: 2009-06-15 Interventions: Procedure: Erbium-YAG laser vaporization spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequen |
Completed |
Study Name: Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1 Condition: Neurofibromatosis Type 1 Cutaneous Neurof Date: 2009-03-17 Interventions: Drug: Imiquimod 5% Cream Applied topically to three tumors 5 times per week for a full 6 weeks |
Active, not recruiting |
Study Name: Medical Treatment of "High-Risk" Neurofibromas Condition: Neurofibromatosis 1 Date: 2009-01-16 Interventions: Drug: Peg-Interferon alpha-2b |
Completed |
Study Name: Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 Condition: Neurofibromatosis Date: 2008-09-16 Interventions: Drug: Pirfenidone Capsule 800 mg TID, oral |
Completed |
Study Name: Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Condition: Neurofibromatosis Type I Plexiform Neurof Date: 2008-07-31 Interventions: Drug: Nexavar (BAY 43-9006) (Sorafenib) Dr |
Terminated |
Study Name: Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas Condition: Neurofibroma Date: 2008-07-14 Interventions: Drug: LS11 LS11 will be given as a one-time IV infusion over 3-5 minutes. |
Completed |
Study Name: Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 Condition: Neurofibromatosis Type 1 Cutaneous Neurof Date: 2008-03-27 Interventions: Drug: Ranibizumab Given as an injection into three cutaneous neurofibromas on day 1 of the study treatme |